Our vision is to redefine synthetic lethality, turning cancer patients into cancer survivors.
Tessellate BIO's approach is unique
- Truly pioneering approach to synthetic lethality: tackling the areas of highest medical need through new targets beyond HRD
- Driven by profound scientific understanding: leading scientists as founders and key strategic advisors
- A ‘drug hunter’ model: bringing together best international science and proven drug development experience to create first-in-class pipeline
- Tumor agnostic: dependent on cancer genotype or phenotype rather than tissue of action
- Committed to precision medicine: companion diagnostics are integral, not an add-on
An excellent blend of pharma and biotech R&D experience with a proven track record of drug development from patent to patient.
We’re building a pipeline of first-in-class medicines based on cutting-edge research, sourced from international world-renowned laboratories
News & events
Stay up to date with our latest developments here
We’re expanding – join us on this exciting journey!